Early successes in identifying and targeting individual oncogenic drivers, together with the
increasing feasibility of sequencing tumor genomes, have brought forth the promise of …

Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15
cases/106/year without any major geographic or ethnic differences [1]. The median age at …

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Background Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some
patients with chronic myeloid leukaemia with deep molecular responses; however, patients …

BACKGROUND Several studies have demonstrated that approximately one‐half of patients
with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors …

Chronic myeloid leukemia (CML) is the best example of successful targeted therapy. Today,
the overall survival of patients with CML treated by using tyrosine kinase inhibitors (TKIs) is …

BACKGROUND We recently reported that peroxisome proliferator‐activated receptor γ
agonists target chronic myeloid leukemia (CML) quiescent stem cells in vitro by decreasing …